SARS-CoV Infection Clinical Trial
— EPI-COVID-19Official title:
Household Transmission Investigation Study for Coronavirus Disease 2019 (COVID-19) in Tropical Regions
Verified date | February 2022 |
Source | Institut Pasteur |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is a interventional study that present minimal risks and constraints to evaluate the presence of novel coronavirus (SARS-CoV-2) or antibodies among individuals living in households where there is a confirmed coronavirus case in order to provide useful information on the proportion of symptomatic forms and the extent of the virus transmission in tropical regions such as French Guiana, Guadeloupe and New-Caledonia.
Status | Completed |
Enrollment | 245 |
Est. completion date | September 30, 2021 |
Est. primary completion date | September 30, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Primary case: laboratory-confirmed coronavirus SARS-CoV-2 infection by polymerase chain reaction (PCR), or Family contact in French Guiana and Guadeloupe: person who lived in the same household as the primary case of COVID-19 when the primary case was symptomatic. A household is defined as a group of people (2 or more) living in the same accommodation (excluding residential institutions such as boarding schools, dormitories, hostels, prisons, other communities hosting grouped people), or Close contact in New-Caledonia: any individual who was in contact with a primary case, in his/her family/living environment, work/school, friends/leisure or means of transport, when the primary case was symptomatic or presymptomatic, - Affiliated or beneficiary of a social security system - Informed consent prior to initiation of any study procedures from subject (or legally authorized representative) - State of health compatible with a blood sample as defined in the protocol. Exclusion Criteria: - Inability to consent - Person under guardianship or curatorship - Known pathology or a health problem contraindicated with the collect of blood sample. |
Country | Name | City | State |
---|---|---|---|
French Guiana | Centre Hospitalier Andrée Rosemon | Cayenne | |
French Guiana | Institut Pasteur de la Guyane | Cayenne | |
Guadeloupe | Institut Pasteur de Guadeloupe | Les Abymes | |
New Caledonia | Institut Pasteur de Nouvelle-Calédonie | Nouméa |
Lead Sponsor | Collaborator |
---|---|
Institut Pasteur | Centre Hospitalier Andrée Rosemon de Cayenne, Centre Hospitalier de la Guadeloupe, Centre Hospitalier Territorial de Nouvelle-Calédonie, Institut Pasteur de la Guadeloupe, Institut Pasteur de la Guyane, Institut Pasteur de Nouvelle-Calédonie |
French Guiana, Guadeloupe, New Caledonia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evaluation of the extent of the virus transmission within households | The extent of the virus transmission within households will be assessed by evaluating the rate of intra-household secondary transmission of the virus | 2 years | |
Secondary | Characterization of the secondary cases | The characterization of the secondary cases will be assessed by evaluating the proportion of asymptomatic forms within the household | 2 years | |
Secondary | Characterization of the secondary cases | The characterization of the secondary cases will be assessed by characterizing the risk factors for coronavirus infection. | 2 years | |
Secondary | In New-Caledonia, evaluation of the extent of the virus transmission within contact persons | The extent of the virus transmission within contact persons will be assessed by evaluating the rate of extended-contact secondary transmission of the virus | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546776 -
COVID-19 Persistence in Stool
|
||
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Completed |
NCT05065827 -
Lung Ultrasound Findings in Patients With COVID-19 in a UK ED
|
||
Completed |
NCT04542915 -
COVID-19-Related Health and Practices Among Dental Hygienists
|
||
Recruiting |
NCT04615052 -
Home-based Exercise in COVID-19 Survivors
|
N/A | |
Enrolling by invitation |
NCT04659486 -
Adolescents With COVID-19/MIS-C at HCFMUSP
|
N/A | |
Recruiting |
NCT04885452 -
Prevention of COVID-19 Complications in High-risk Subjects Infected by SARS-CoV-2 and Eligible for Treatment Under a Cohort ATU ('Autorisation Temporaire d'Utilisation') OR or Authorisation for Early Access (AAP). A Prospectvie Cohort.
|
||
Completed |
NCT05063812 -
Performance of a Remote Monitoring Program for Patients Diagnosed With COVID-19
|
||
Completed |
NCT04516928 -
Study of SARS-CoV2 Virus (COVID-19) Seroprevalence Among Lyon-Bron Military Health Schools Personnel
|
||
Completed |
NCT04530357 -
Reactogenicity, Safety and Immunogenicity of QazCovid-in® COVID-19 Vaccine
|
Phase 1/Phase 2 | |
Recruiting |
NCT04565782 -
Corona Virus Infection Among Liver Transplant Recipients
|
||
Completed |
NCT04733625 -
The Effect of Vitamin D Therapy on Morbidity and Moratlity in Patients With SARS-CoV 2 Infection
|
N/A | |
Completed |
NCT04550390 -
Study of the Analytical Performance of Different Salivary Self-collection Methods for the Detection of COVID-19
|
||
Active, not recruiting |
NCT04517136 -
Impact of Perceived Control on Operational Strain: a Study of COVID-19 Pandemic Caregivers and Military Personnel on Operational Missions
|
||
Recruiting |
NCT04476680 -
Influence of Military Preventive Policy for reCruit Training on COVID-19 Seroconversion
|
N/A | |
Completed |
NCT04839913 -
Seroprevalence of SARS-CoV-2 in Unselected Surgical Patients: an Unicentric, Regional Study
|
||
Completed |
NCT04514874 -
Assessment of the Prevalence and the Impact of the COVID-19 Epidemic in the French Flight Crew in 2020
|
||
Terminated |
NCT04606563 -
Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?
|
Phase 3 | |
Completed |
NCT05234359 -
The CHILD Cohort COVID-19 Add-On Study
|